Welcome to our dedicated page for Dogwood Therapeutics SEC filings (Ticker: DWTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Dogwood Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Dogwood Therapeutics's regulatory disclosures and financial reporting.
Dogwood Therapeutics, Inc. held its annual stockholder meeting, where investors approved an amendment to the Certificate of Incorporation to increase the number of authorized common and preferred shares. Stockholders also elected seven directors, ratified Forvis Mazars, LLP as auditor for 2026, and endorsed executive pay.
Holders of 31,791,500 common shares, representing 95.17% of the voting power as of the record date, were present in person or by proxy, providing a strong quorum. Stockholders supported holding advisory votes on executive compensation every year, and the Board agreed to include this annual vote in future proxy materials.
Dogwood Therapeutics, Inc. director Abel De La Rosa received a grant of stock options, giving the right to buy 16,800 shares of common stock. The options have an exercise price of $1.50 per share and were awarded at no cost as equity compensation.
After this grant, De La Rosa holds stock options for 16,800 underlying shares directly. The options become exercisable starting on June 16, 2027 and expire on June 16, 2036, providing long-term potential ownership if exercised in the future.
Thomas John C reported acquisition or exercise transactions in this Form 4 filing.
Dogwood Therapeutics director Thomas John C received a grant of stock options giving him the right to buy 16,800 shares of common stock at $1.50 per share. These options expire on June 16, 2036 and are held directly, with 16,800 derivative securities reported following the grant. This is a compensation-related award rather than an open-market purchase or sale.
Dogwood Therapeutics director Richard James Whitley received a grant of stock options for 16,800 shares of Common Stock. The options carry an exercise price of $1.50 per share, become exercisable on June 16, 2027, and expire on June 16, 2036. Following this award, he holds 16,800 derivative securities directly.
Dogwood Therapeutics director David R. Keefer received a new stock option grant for 16,800 shares of common stock. The options have an exercise price of $1.50 per share, allowing him to buy shares at that price in the future. Following this grant, he holds 16,800 options directly. The options become exercisable starting June 16, 2027 and expire on June 16, 2036, making this a long-term, compensation-related award rather than an open-market trade.
Armistice Capital, LLC and Steven Boyd reported beneficial ownership of 3,343,120 shares of Dogwood Therapeutics, Inc. common stock, representing 9.99% of the class. The filing states shared voting and dispositive power over those shares and identifies Armistice Capital as investment manager for the Master Fund. The joint filing is signed by Steven Boyd on 05/15/2026.
Dogwood Therapeutics, Inc. filed its Form 10-Q reporting first-quarter 2026 results as a pre-revenue, development-stage biopharmaceutical company focused on cancer pain and neuropathy. The company posted a net loss of $4,986,614 for the three months ended March 31, 2026, narrowing from $10,924,952 a year earlier, as total operating expenses were $5,076,366.
Cash and cash equivalents increased to $13,227,839 at March 31, 2026 from $6,524,744 at year-end 2025, helped by net proceeds of about $11.4M from a January 2026 equity and warrant financing. The accumulated deficit reached $113,062,930, and management states that existing cash will not fund operations for at least 12 months, indicating substantial doubt about the company’s ability to continue as a going concern without additional financing.
Dogwood Therapeutics reported first quarter 2026 results, highlighting pipeline progress and stronger finances. The company recorded no revenue, with research and development expenses of $2.7 million and general and administrative expenses of $2.4 million, both modestly higher than a year earlier.
Net loss attributable to common stockholders narrowed to $5.0 million, or $0.15 per share, from $12.2 million, or $8.45 per share, in the first quarter of 2025. Cash and cash equivalents increased to $13.2 million as of March 31, 2026.
Operationally, Halneuron® remains on track for Phase 2b top-line data in chemotherapy-induced neuropathy in fall 2026, and SP16 advanced with FDA acceptance of its investigational new drug application and planned Phase 1b development. Dogwood also announced a worldwide development and commercialization partnership for legacy antiviral assets with potential value up to $100 million for the company and its current and former shareholders.
Dogwood Therapeutics, Inc. is asking stockholders to vote at a virtual annual meeting on June 16, 2026. The ballot includes electing seven directors, ratifying Forvis Mazars, LLP as auditor, and advisory Say‑on‑Pay and Say‑on‑Frequency votes.
A key item is a proposal to amend the Certificate of Incorporation to increase authorized common stock from 43,000,000 to 195,000,000 shares and preferred stock from 2,000,000 to 5,000,000 shares, giving the company more flexibility for financing and equity incentives. As of April 26, 2026, 33,401,553 common shares were outstanding. Sealbond Limited beneficially owns 21,822,333 shares, or 65.3%, and Conjoint, Inc. owns 2,842,638 shares, or 8.5%.
The proxy details board structure, committee independence, and executive pay. In 2025, CEO Greg Duncan received total compensation of $3,344,728, while other named executives also received salary, cash bonuses and significant option awards under the company’s 2020 Equity Incentive Plan, which authorizes up to 2,972,787 shares for equity grants.